Click to read a spotlight on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) from drug development IP to pipeline.
TheSeedInvestor
Read our Medical Marijuana Compound Report for Free Today!
13x13x1 READ MORE
Read the Investors Guide To Newly Emerging Marijuana Markets 
LEARN MORE

Dear Seed Investor, 

UNDERSTANDING INMED: Drug Development IP to Pipeline.

Cannabis Biotechs lead the Bloomberg Weed Index* this year, and one of the reasons InMed is poised to explode. Already up over ~400% year over year...they continue innovating in the space.

To understand the reasons why InMed is so well positioned in this Billion dollar space, Visual Capitalist profiled the Company with
an Infographic.

Click the image below to view the full Company Spotlight (InMed Infographic)



High Profits, 

The Seed Investor

Bloomberg Weed Index Click Here:  *https://www.bloomberg.com/graphics/2017-weed-index/

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
 
32x32x1   32x32x2  
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
 
©2019, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.